Results

• All
• Video
• Audio
• Images

• Most recent

1–1 of 1 result for jak inhibitor

• 

  Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase 2 Study (NEPTUNE)

  Robert C. Wang, MD, FASRS

  Annual Meeting Talks

  2024